Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction

Vivos Inc. received FDA approval for its Investigational Device Exemption (IDE) to initiate a first-in-human feasibility study for RadioGel® at Mayo Clinic, targeting non-resectable papillary thyroid carcinoma patients. The company is expanding its animal therapy business with 17 certified clinics treating over 200 animals, establishing dual manufacturing facilities in the U.S. and India, and preparing for international clinical trial expansion with strong interest from multiple countries.